CAM
KRYS icon

Congress Asset Management’s Krystal Biotech KRYS Stock Holding History

Congress Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18M Buy
54,083
+13,949
+35% +$4.83M 0.12% 159
2026
Q2 		$14.9M Buy
+40,134
New +$12M 0.09% 174

Other funds holding KRYS

TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
RWS
Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
NWMP
Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return

Congress Asset Management's KRYS Position: Q3 2026 in Review

Congress Asset Management increased its Krystal Biotech (KRYS) stake by 35% in Q3 2026, buying an estimated $4.83M and bringing the position to 54,083 shares worth $18M. The position accounts for 0.12% of the portfolio, ranked #159.

Congress Asset Management first reported a position in KRYS in Q2 2026 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Congress Asset Management held 54,083 shares of Krystal Biotech worth $18M as of Q3 2026.
  • Congress Asset Management bought 13,949 Krystal Biotech shares in Q3 2026, an estimated $4.83M.
  • Krystal Biotech made up 0.12% of Congress Asset Management's portfolio in Q3 2026, its #159 holding.
  • Congress Asset Management first reported a position in Krystal Biotech in Q2 2026 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Congress Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.